J. Christopher Naftzger - Feb 4, 2025 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Signature
/s/ David C. Hastings as attorney-in-fact for J. Christopher Naftzger
Stock symbol
ABUS
Transactions as of
Feb 4, 2025
Transactions value $
-$37,206
Form type
4
Date filed
2/5/2025, 04:02 PM
Previous filing
Feb 5, 2024
Next filing
Feb 19, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABUS Common Shares Sale -$37.2K -11.3K -11.61% $3.28 86.2K Feb 4, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on July 11, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units.
F2 Includes 1,214 and 1,263 shares acquired under the Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan on February 29, 2024 and August 30, 2024, respectively.